Baseline characteristics

Slides:



Advertisements
Similar presentations
Positive Implications of Initiating Insulin Pump Therapy at Diagnosis of Type 1 Diabetes Ramchandani, Neesha 1 ; Ten, Svetlana 1 ; Anhalt, Henry 2 ; Sinha,
Advertisements

In the name of GOD In the name of GOD.
Nallasamy K, Jayashree M, Singhi S, Bansal A
Managing T2DM during Ramadan Dr. Asrar Said Hashem Specialist in Internal Medicine (Al-Amiri Hospital) Fellow of KIMS Endocrine, Diabetes and Metabolism.
Canadian Diabetes Assocaition Clinical Practice Guidelines Pharmacotherapy in Type 1 Diabetes Chapter 12 Angela McGibbon, Cindy Richardson, Cheri Hernandez,
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.
Diabetes Control in Youth: The American Experience Georgeanna J. Klingensmith, MD Keystone Colorado July 2008.
Afrezza® – inhaled human insulin
INSULIN THERAPY IN TYPE 1 DIABETES
Sugar control in Critical care unit Senior clinical pharmacist : Lihua Fang Koo Foundation Cancer Center.
PRE-EXISTING DIABETES AND PREGNANCY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Summary of Revisions for the 2013 Clinical Practice Recommendations Copied from:
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Diabetes: What’s New? What’s Next? Robert P. Hoffman, M.D. Grand Rounds June 1, 2007.
Use of The FreeStyle Navigator TM Continuous Glucose Monitoring System in Children on Glargine- based Multiple Daily Injection Therapy Stuart Weinzimer.
دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد INSULIN THERAY IN TYPE 1 DIABETES.
Dr Stanley Ngare.  Pharmacology of Types of insulin available  Various routes of delivery & factors that affect absorption  Patient and provider barriers.
Endocrine and Metabolic Disorders Lectures 8 I.Kuziv, MD, PhD.
Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes A pilot, randomized,
Tresiba- insulin degludec
Achieving Glycemic Control in the Hospital Setting (Part 2 of 4)
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年5月1日 8:20-8:50 B 棟8階 カンファレンス室.
Medical Management of Diabetes During Ramadan Jennifer Hamilton, MD August, 2007 CE Rajab, 1428 AH.
Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomized open-label controlled trial Yves.
Zainudin S 1, Ang DY 2, Goh SY 1, Soh AW 1. Department of Endocrinology, Singapore General Hospital, Singapore 1 ; Yong Loo Lin, School of Medicine, National.
Strategies to Reduce Hypoglycemia Presented by: Hennie Garza, M.S., R.Ph., C.D.E, Director of Pharmacy Utilization and Outcomes Senior Care Centers
Date of download: 6/24/2016 From: Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus: A Systematic.
Date of download: 6/26/2016 From: Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus: A Systematic.
Changes in the concentration of serum C-peptide in type 2 diabetes during long-term continuous subcutaneous insulin infusion therapy Department of Internal.
Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.
 Insulin Degludec  Ultra long action  Due to formation of soluble multihexamers at the injection site from which monomers gradually separate and are.
A two stage screening process – the pre-diabetes pathway.
Glycemia Treatment Strategies Used In ACCORD
To Pump OR To Inject … that is the Question … ?
CAN WE IMPROVE POSTPRANDIAL GLUCOSE CONTROL WITH FAST-ACTING INSULINS?
Key publication slides
Nallasamy K, Jayashree M, Singhi S, Bansal A
HbA1c before Ramadan (%)
Figure 1. Onset of PIV catheter complications
Safety and efficacy of insulin guideline for controlling perioperative hyperglycemia Marwa Amer PharmD Candidate1, Mark Shelly MD2, Dianne Lee PharmD Candidate1,
Use of Insulin Pump in Children with Type I Diabetes Mellitus: Effect on glycemic control and Body Mass Indices (BMI). Noura Al Hemaidi, Maryam Al Ali,
Key publication slides
Copyright © 2004 American Medical Association. All rights reserved.
Insulin Detemir versus Glyburide in Women with
W.S.T. Swarnasri1, Noel P. Somasundaram2
Faster-Acting Insulins
Diabetes Self-Management Education and Support: Component of Standard Diabetes Care 1, 2 “… Ongoing patient self-management education and support are.
Continuous Subcutaneous Insulin Infusion (CSII) [Insulin Pump]
Utilizing New Technologies and Insulins for a Tighter Grip on PPG
Accepted 2 June Ryan Chen
Faster-Acting Insulins
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Treatment Pathway for Adults with Type 1 Diabetes
The Research Question Does self monitoring of blood glucose (SMBG) in patients with non-insulin treated type 2 diabetes improve glycemia or quality of.
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Modern Advances in Glucose Monitoring
Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?
Hba1c for diagnosis Dr Karen Adamson.
Campbell FM, et al. Pediatr Diabetes. 2018;19(7):1294–1301
INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.
Diabetes Self-Management Education and Support: Component of Standard Diabetes Care 1, 2 “… Ongoing patient self-management education and support are.
Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).
Medication Therapy During the Holy Month of Ramadan
PowerPoint 16:9 Screen Ratio Template *
Insulin Delivery Systems Atlanta Diabetes Associates
MANDATORY INSULIN EDUCATION
Cost-Efficiency of Medication Safety Program at Public Hospital, Riyadh, Saudi Arabia Yousef Ahmed Alomi, Mona Awad Alanazi, Radi Abdullah Alattyh, Fatimah.
Twice daily regimen N=45 MDI regimen N=28 P Value
Presentation transcript:

Baseline characteristics Incidence of Hypoglycemia in Type1 Diabetes Patients who fast Ramadan; Insulin Pump Compared to Multi-Dose Injection using Insulin Glargine and Aspart Drs. Reem Al Amoudi *, Maram AlSubaiee , Ali Al Qarni , Yousef Saleh , Saleh Aljaser , Waleed AlTamimi and AbdulSalam Endocrinology Section, National Guard Health Affairs, King Abdullah International Medical Research Center , KSA Introduction Fasting the holy month of Ramadan is associated with risk of hypoglycemia and other acute glycemic disturbances. Though exempt from fasting many patients with type1 diabetes (T1DM) choose to fast. The effect of fasting during Ramadan on rate of hypoglycemia is not known with certainty and managing T1DM during fasting is very challenging. Very few studies have documented the safety and efficacy of different insulin regimens on fasting. Continuous subcutaneous insulin infusion (CSII) management offers the advantage of flexibility and precision to administering insulin and has been proven to reduce severe hypoglycemia compared to multi-dose insulin injection (MDI). Objective Primary Objective : To determine if insulin pump users have less rates of hypoglycemia during fasting Ramadan compared to MDI users [Hypoglycemia defined as blood glucose level ≤ 70 mg/dl ( 3.9 mmol/l)] Secondary Objectives: To estimate the difference between the two groups in: Number of days they needed to brake their fast due to acute complications (hypoglycemia, severe hyperglycemia or DKA). Glycemic control.   Overnight hyperglycemia. Rate of severe hyperglycemia and /or DKA. Methods A small cohort of patients with T1DM above the age of 14-years on either CSII or MDI, and who fast Ramadan were recruited from three diabetes/ Endocrine clinics in three different cities in Saudi Arabia (Dammam, Alahsa and Riyadh). Demographic data and data on glycemic control were collected before, during, and after Ramadan using questionnaire , glucometer ( SMBG ) and continues glucose monitoring (CGM) data Methods Results Results . Results Study flow chart Baseline characteristics Conclusions Fasting Ramadan is well tolerated in patients with T1DM on both MDI and Pump therapy with no major complications Although mild hypoglycemia is more in pump , MDI is associated with higher rate of sever hypoglycemia and number of days needed to break fasting. Glycemic control ( as indicated by A1c ) was generally better in Pump than MDI , but it worsened with fasting in both groups Acute diabetes complications requiring hospitalization are very rare and in our study only occurred in two patients on MDI group Funding Institution : King Abdullah International Medical Research Center PI contact * : amoudir@ngha.med.sa References Ali G, Fasting of persons with diabetes mellitus during Ramadan. Diabetologia Croatica, 2002 Al-Arouj M Recommendations for Management of Diabetes During Ramadan , 2010 Colquitt JL, Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. 2004